dyslipidemia
DYSLIPIDEMIA
Dyslipidemia is having an abnormal amount of lipids or fats in the blood.
Lipid profile is obtained from an individual with diabetes mellitus, coronary heart disease, cerebrovascular disease, peripheral arterial disease or other coronary heart disease risk factors or from an individual with family history or clinical evidence of familial hypercholesterolemia.
Plasma lipids are total cholesterol, high-density lipoprotein cholesterol, trigylcerides, and low-density lipoprotein cholesterol.
Evaluation of lipid profile must be performed in parallel with the risk assessment of coronary heart disease.

Definition

  • An abnormality in lipoprotein metabolism that results in elevations of low-density lipoprotein cholesterol (LDL-C), total cholesterol, triglycerides, and/or non-high-density lipoprotein cholesterol (non-HDL-C) levels, or significantly reduced high-density lipoprotein cholesterol (HDL-C) levels
  • Increase in serum concentration of total cholesterol, LDL, triglycerides or non-HDL-C is equivalent to increased risk for cardiovascular diseases

Etiology

  • Depends on the type of dyslipidemia
  • Hereditary disorders associated with dyslipidemia include familial hypercholesterolemia, familial hypertriglyceridemia, familial combined hyperlipidemia, familial dysbetalipoproteinemia, chylomicronemia
  • Secondary causes include diabetes mellitus, diet, alcohol intake, hypothyroidism, renal failure, obstructive liver disease, Cushing’s syndrome, metabolic syndrome, medications (glucocorticoids, beta-blockers, thiazides, estrogen therapy)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
11 Aug 2019
Intraoperative methylprednisolone does not appear to significantly prevent the incidence of death, cardiac arrest and other injuries in neonates undergoing cardiac surgery with cardiopulmonary bypass, according to a recent study.
11 Aug 2019
Treatment with low-to-standard dose dual combination therapy of blood pressure (BP)-lowering drugs is more effective than standard-dose monotherapy and does not increase withdrawals due to adverse events, a recent study has shown.
20 Jun 2019
Untreated white coat hypertension (WCH), but not treated white coat effect (WCE), may increase the risk for cardiovascular events and all-cause mortality, suggest the results of a systematic review and meta-analysis. Out-of-office blood pressure (BP) monitoring is thus important in the diagnosis and management of hypertension.
06 Aug 2019
Risk factors for 1-year mortality in heart failure (HF) patients significantly differ between those with and without chronic kidney disease (CKD), especially with regard to the use of beta-blockers or diuretics at discharge, according to a study. This suggests that these patients may benefit from individualized therapies.